<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250603066054N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-06-20</date_registration>
      <primary_sponsor>Self-funded by the investigators</primary_sponsor>
      <public_title>Considering the effect of Two Cardiac Rehabilitation Approaches in Middle-Aged and Elderly Men with Coronary Artery Disease</public_title>
      <acronym>Cardiac Rehabilitation/Secondary Prevention (CRSP)</acronym>
      <scientific_title>Comparative Effectiveness of Two Cardiac Rehabilitation Approaches in Middle-Aged and Elderly Men with Coronary Artery Disease</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-07-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/84133</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: This study used a randomized controlled trial design. Thirty-two men with coronary artery disease were randomly assigned to two intervention groups: aerobic training and concurrent (combined) training. Participants were stratified by age (middle-aged and elderly) and then randomly allocated within each stratum using a simple randomization method. Randomization was conducted by an independent researcher using a random number table. Allocation concealment was maintained through coded identifiers, and outcome assessors were blinded to group assignments, Blinding description: Due to the nature of the intervention (supervised exercise training), blinding of participants, care providers, and investigators was not feasible. However, outcome assessors and data analysts were blinded to group allocation to minimize detection and analysis bias. This single-blind approach helped ensure objectivity in data evaluation and result interpretation.</study_design>
      <phase>2</phase>
      <hc_freetext>Cardiovascular disease including myocardial infarction in men aged 45 to 65.</hc_freetext>
      <i_freetext>Aerobic Exercise Group:Three weekly sessions of aerobic training including warm-up, main activities (cycling and elliptical at 50–80% max heart rate), and cool-down, with gradual increase over 8 weeks.Aerobic-Resistance Exercise Group:Same aerobic protocol plus two weekly resistance training sessions targeting major muscle groups at 30–50% one-rep max, 12–15 reps..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Title: Clinical Trial Data on Cardiac Rehabilitation in Middle-Aged and Elderly Men with Coronary Artery Disease
Details: This dataset includes de-identified participant data collected during pre- and post-intervention phases of the cardiac rehabilitation study, including demographic information, physiological measurements (blood pressure, heart rate, echocardiography results), and exercise protocol details.

When:
The data will be available starting 6 months after the publication of the study results. The dataset will remain accessible for a minimum of 5 years through an online data repository.

To whom:
Available to researchers upon request

Conditions:
The data will be available for academic and research purposes only. Users must agree to a data use agreement ensuring confidentiality and ethical use. Access to the data will be granted after approval by the principal investigator.
Additional note: If the journal requests, the data and related documents will be made available to the journal editors and reviewers upon reasonable request to verify the study findings.

Where to obtain:
Data and documents will be available from the corresponding author upon reasonable request.

How to obtain:
Interested researchers should submit a formal request via email to the corresponding author detailing the purpose of data use. The request will be reviewed by the principal investigator for approval. Upon approval, a data use agreement ensuring confidentiality and ethical use must be signed. After completing these steps, access to data/documents will be granted.

Comments:
No additional comments.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Heydar.Sadeghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Physical Education and Sport Sciences, Kharazmi University, End of Southern Razan (Shahid Hessari) Street, next to Shahid Keshvari Sports Complex, Mohseni (Mirdamad) Square, Mirdamad Blvd., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3311115447</zip>
        <telephone>0212228001</telephone>
        <email>h.sadeghi@khu.ac.ir</email>
        <affiliation>Kharazmi University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Heydar Sadeghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Physical Education and Sport Sciences, Kharazmi University, End of Southern Razan (Shahid Hessari) Street, next to Shahid Keshvari Sports Complex, Mohseni (Mirdamad) Square, Mirdamad Blvd., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3311115447</zip>
        <telephone>+98 21 2222 8001</telephone>
        <email>h.sadeghi@khu.ac.ir</email>
        <affiliation>Kharazmi University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Middle-aged men (45-65 years) with myocardial infarction
Physician’s approval for participation in the exercise program
Non-smokers
No alcohol consumption</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>65 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Presence of warning signs during exercise
Unstable angina pectoris
Dyspnea at rest or severe arrhythmias
Chronic diseases causing discomfort during exercise
ST segment elevation or depression on ECG during exercise
Respiratory disturbances during exercise
Inability or unwillingness to complete the exercise program</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>ICD-10: I2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Ischemic heart diseases (I20–I25)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Aerobic Exercise Group:Three weekly sessions of aerobic training including warm-up, main activities (cycling and elliptical at 50–80% max heart rate), and cool-down, with gradual increase over 8 weeks.Aerobic-Resistance Exercise Group:Same aerobic protocol plus two weekly resistance training sessions targeting major muscle groups at 30–50% one-rep max, 12–15 reps.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Primary outcomes include changes in systolic and diastolic blood pressure, resting heart rate, left ventricular ejection fraction, and cardiac capacity and performance as assessed by stress testing, measured before and after the 8-week intervention. Timepoint: Primary outcome variables will be measured at two time points: baseline (before the intervention) and immediately after the 8-week exercise program. Method of measurement: Systolic Blood Pressure: Measured using a blood pressure monitor in mmHg.Diastolic Blood Pressure: Measured using a blood pressure monitor in mmHg.Resting Heart Rate: Measured by counting heartbeats per minute at rest.Left Ventricular Systolic Function: Calculated by echocardiography using ejection fraction (stroke volume/end-diastolic volume).Cardiac Capacity and Performance: Assessed using a cardiac stress test (exercise test).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Supervisor’s funding</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-06-01</approval_date>
        <contact_name>Kharazmi University Ethics Committee</contact_name>
        <contact_address>Kharazmi University, Shahid Haghani Highway, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
